Cargando…
Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics
Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Th...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503093/ https://www.ncbi.nlm.nih.gov/pubmed/36142502 http://dx.doi.org/10.3390/ijms231810587 |
_version_ | 1784795877110448128 |
---|---|
author | Krencz, Ildikó Vetlényi, Enikő Dankó, Titanilla Petővári, Gábor Moldvai, Dorottya Sztankovics, Dániel Raffay, Regina Mészáros, Katalin Sebestyén, Endre Végső, Gyula Pápay, Judit Sebestyén, Anna |
author_facet | Krencz, Ildikó Vetlényi, Enikő Dankó, Titanilla Petővári, Gábor Moldvai, Dorottya Sztankovics, Dániel Raffay, Regina Mészáros, Katalin Sebestyén, Endre Végső, Gyula Pápay, Judit Sebestyén, Anna |
author_sort | Krencz, Ildikó |
collection | PubMed |
description | Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Therefore, our study aimed to analyze the in situ metabolic features of PRCC vs. CCRCC tissues and compared the metabolic characteristics of PRCC, CCRCC, and normal tubular epithelial cell lines. The protein and mRNA expressions of the molecular elements in mammalian target of rapamycin (mTOR) and additional metabolic pathways were analyzed in human PRCC cases compared to CCRCC. The metabolic protein expression pattern, metabolite content, mTOR, and metabolic inhibitor sensitivity of renal carcinoma cell lines were also studied and compared with tubular epithelial cells, as “normal” control. We observed higher protein expressions of the “alternative bioenergetic pathway” elements, in correlation with the possible higher glutamine and acetate consumption in PRCC cells instead of higher glycolytic and mTOR activity in CCRCCs. Increased expression of certain metabolic pathway markers correlates with the detected differences in metabolite ratios, as well. The lower lactate/pyruvate, lactate/malate, and higher pyruvate/citrate intracellular metabolite ratios in PRCC compared to CCRCC cell lines suggest that ACHN (PRCC) have lower Warburg glycolytic capacity, less pronounced pyruvate to lactate producing activity and shifted OXPHOS phenotype. However, both studied renal carcinoma cell lines showed higher mTOR activity than tubular epithelial cells cultured in vitro, the metabolite ratio, the enzyme expression profiles, and the higher mitochondrial content also suggest increased importance of mitochondrial functions, including mitochondrial OXPHOS in PRCCs. Additionally, PRCC cells showed significant mTOR inhibitor sensitivity and the used metabolic inhibitors increased the effect of rapamycin in combined treatments. Our study revealed in situ metabolic differences in mTOR and metabolic protein expression patterns of human PRCC and CCRCC tissues as well as in cell lines. These underline the importance in the development of specific new treatment strategies, new mTOR inhibitors, and other anti-metabolic drug combinations in PRCC therapy. |
format | Online Article Text |
id | pubmed-9503093 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95030932022-09-24 Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics Krencz, Ildikó Vetlényi, Enikő Dankó, Titanilla Petővári, Gábor Moldvai, Dorottya Sztankovics, Dániel Raffay, Regina Mészáros, Katalin Sebestyén, Endre Végső, Gyula Pápay, Judit Sebestyén, Anna Int J Mol Sci Article Metabolic characteristics of kidney cancers have mainly been obtained from the most frequent clear cell renal cell carcinoma (CCRCC) studies. Moreover, the bioenergetic perturbances that affect metabolic adaptation possibilities of papillary renal cell carcinoma (PRCC) have not yet been detailed. Therefore, our study aimed to analyze the in situ metabolic features of PRCC vs. CCRCC tissues and compared the metabolic characteristics of PRCC, CCRCC, and normal tubular epithelial cell lines. The protein and mRNA expressions of the molecular elements in mammalian target of rapamycin (mTOR) and additional metabolic pathways were analyzed in human PRCC cases compared to CCRCC. The metabolic protein expression pattern, metabolite content, mTOR, and metabolic inhibitor sensitivity of renal carcinoma cell lines were also studied and compared with tubular epithelial cells, as “normal” control. We observed higher protein expressions of the “alternative bioenergetic pathway” elements, in correlation with the possible higher glutamine and acetate consumption in PRCC cells instead of higher glycolytic and mTOR activity in CCRCCs. Increased expression of certain metabolic pathway markers correlates with the detected differences in metabolite ratios, as well. The lower lactate/pyruvate, lactate/malate, and higher pyruvate/citrate intracellular metabolite ratios in PRCC compared to CCRCC cell lines suggest that ACHN (PRCC) have lower Warburg glycolytic capacity, less pronounced pyruvate to lactate producing activity and shifted OXPHOS phenotype. However, both studied renal carcinoma cell lines showed higher mTOR activity than tubular epithelial cells cultured in vitro, the metabolite ratio, the enzyme expression profiles, and the higher mitochondrial content also suggest increased importance of mitochondrial functions, including mitochondrial OXPHOS in PRCCs. Additionally, PRCC cells showed significant mTOR inhibitor sensitivity and the used metabolic inhibitors increased the effect of rapamycin in combined treatments. Our study revealed in situ metabolic differences in mTOR and metabolic protein expression patterns of human PRCC and CCRCC tissues as well as in cell lines. These underline the importance in the development of specific new treatment strategies, new mTOR inhibitors, and other anti-metabolic drug combinations in PRCC therapy. MDPI 2022-09-13 /pmc/articles/PMC9503093/ /pubmed/36142502 http://dx.doi.org/10.3390/ijms231810587 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Krencz, Ildikó Vetlényi, Enikő Dankó, Titanilla Petővári, Gábor Moldvai, Dorottya Sztankovics, Dániel Raffay, Regina Mészáros, Katalin Sebestyén, Endre Végső, Gyula Pápay, Judit Sebestyén, Anna Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title_full | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title_fullStr | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title_full_unstemmed | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title_short | Metabolic Adaptation as Potential Target in Papillary Renal Cell Carcinomas Based on Their In Situ Metabolic Characteristics |
title_sort | metabolic adaptation as potential target in papillary renal cell carcinomas based on their in situ metabolic characteristics |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503093/ https://www.ncbi.nlm.nih.gov/pubmed/36142502 http://dx.doi.org/10.3390/ijms231810587 |
work_keys_str_mv | AT krenczildiko metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT vetlenyieniko metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT dankotitanilla metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT petovarigabor metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT moldvaidorottya metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT sztankovicsdaniel metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT raffayregina metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT meszaroskatalin metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT sebestyenendre metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT vegsogyula metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT papayjudit metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics AT sebestyenanna metabolicadaptationaspotentialtargetinpapillaryrenalcellcarcinomasbasedontheirinsitumetaboliccharacteristics |